Interní Med. 2014; 16(5): 189-191

News in treatment of idiopathic pulmonary fibrosis

doc.MUDr.Martina Vašáková, Ph.D.
Pneumologická klinika 1. LF UK, Thomayerova nemocnice Praha

Idiopathic pulmonary fibrosis (IPF) is diffuse primarily fibrosing lung process of unknown etiology. The main clinical signs of IPF are middle

and advanced age of patient, otherwise unexplainable breathelesness, clubbed fingers and crepitus on auscultation. The main investigation

for diagnosis is CT of lungs with high resolution algorythm with finding of usual interstitial pneumonia (UIP). Bronchoalveolar

lavage has rather auxiliary differential diagnostic meaning. In case of uncertainity the diagnosis should be supported by surgical lung

biopsy with histopathologic finding of UIP. The new drug for treatment of IPF with causal action is pirfenidone.

Keywords: idiopathic pulmonary fibrosis, diagnosis, treatment, biologic treatment, pirfenidone

Published: November 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vašáková M. News in treatment of idiopathic pulmonary fibrosis. Interní Med. 2014;16(5):189-191.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Raghu G, et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic Pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med; 2011; 183: 788-824. Go to original source... Go to PubMed...
    2. Strieter RM, Mehrad B. New mechanisms of pulmonary fibrosis. Chest 2009; 136: 1364-1370. Go to original source... Go to PubMed...
    3. Maher TM Idiopathic pulmonary fibrosis: pathobiology of novel approaches to treatment. Clin Chest Med 2012; 33: 69-83. Go to original source... Go to PubMed...
    4. Lota HK, Wells AU. The evolving pharmacotherapy of pulmonary fibrosis.Expert Opin Pharmacother. 2013 Jan; 14(1): 79-89. doi: 10.1517/14656566.2013.758250. Go to original source... Go to PubMed...
    5. Pandit KV, Milosevic J, Kaminski N. MicroRNAs in idiopathic pulmonary fibrosis. Transl Res. 2011 Apr; 157(4): 191-199. doi: 10.1016/j.trsl.2011.01.012. Epub 2011 Feb 4. Go to original source... Go to PubMed...
    6. Toonkel RL, Hare JM, Matthay MA, Glassberg MK. Mesenchymal Stem cells and idiopathic pulmonary fibrosis: Potential for clinical testing. Am J Respir Crit Care Med 2013 Go to original source... Go to PubMed...
    7. Flaherty KR, King TE, Raghu G, et al. Idiopathic interstitial pneumonia. What is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med, 2004; 170: 904-910. Go to original source... Go to PubMed...
    8. Fishbein MC. Diagnosis: to biopsy or not to biopsy: assessing the role of surgical lung biopsy in the diagnosis of idiopathic pulmonary fibrosis. Chest 2005; 128: 520S-525S. Go to original source... Go to PubMed...
    9. Wells AU, Behr J, Costabel U, et al. Triple therapy in idiopathic pulmonary fibrosis: an alarming press release. Eur Repir J 2012; 39: 805-806. Go to original source... Go to PubMed...
    10. The Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, Azathioprine and N-Acetylcysteine for Pulmonary Fibrosis. N Engl J Med 366; 21: 1968-1977. Go to original source... Go to PubMed...
    11. NICE technology appraisal guidance 282 (2013). Pirfenidone for treating idiopathic pulmonary fibrosis. Issued: April 2013.
    12. Costabel U, Albera C, Bradford W, et al Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis Eur Respir J 2012; 40: Suppl. 56, 511s.
    13. Azuma A, Taguchi Y, Ogura et al. Pirfenidone Clinical Study Group in Japan.Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment.Respir Res. 2011 Oct 28; 12: 143. doi: 10.1186/1465-9921-12-143. Go to original source... Go to PubMed...
    14. Swigris JJ, Brown KK, Make BJ, et al. Pulmonary rehabilitation in idiopathic pulmonary fibrosis: A call for continued investigation. Resp Med 2008; 102: 1675-1680. Go to original source... Go to PubMed...
    15. Richeldi L, Costabel U, Selman M, et al. Efficacy of tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365: 1079-1087. Go to original source... Go to PubMed...
    16. Barry-Hamilton V, Spangler R, Marshall D, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nature Medicine 2010; 16: 1009-1017. doi: 10.1038/nm.2208. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.